Unknown

Dataset Information

0

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

ABSTRACT:

SUBMITTER: de Boer SM 

PROVIDER: S-EPMC6722042 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
| S-EPMC5840256 | biostudies-literature
Unknown Recurrence Features and Factors influencing Post-relapse Survival in Early-stage Endometrial Cancer after Adjuvant Radiotherapy.
| S-EPMC8692693 | biostudies-literature
Unknown Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study.
| S-EPMC9297464 | biostudies-literature
Unknown Postoperative Radiotherapy Alone Versus Chemoradiotherapy in Stage I-II Endometrial Carcinoma: An Investigational and Propensity Score Matching Analysis.
| S-EPMC4398106 | biostudies-other
Unknown De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
| S-EPMC6517188 | biostudies-literature
Unknown Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
| S-EPMC9297529 | biostudies-literature
Unknown Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma.
| S-EPMC5620319 | biostudies-literature
Unknown PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
| S-EPMC7788476 | biostudies-literature
Unknown Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
| S-EPMC5834053 | biostudies-literature
Unknown Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
| S-EPMC6219495 | biostudies-literature